Verrica Pharmaceuticals (VRCA) Stock: Buy, Sell, or Hold?
VRCA - Verrica Pharmaceuticals Inc. Common Stock
$4.91
-0.04 (-0.81%)
âŧ
5d:
-8.4%
30d:
-3.54%
90d:
-18.51%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When VRCA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VRCA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VRCA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VRCA is currently trading at $4.91, which is considered slightly low relative to its 30-day fair value range of $4.87 to $5.36.
Technical Outlook: Technically, VRCA is in a downtrend. The price is currently testing key support at $4.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.83 (+181.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRCA is in a downtrend. The price is currently testing key support at $4.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.83 (+181.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.87 -
$5.36
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 181.7% below Wall St target ($13.83)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.87 -
$5.36
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.80
Resistance Level
$5.86
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.32
Wall Street Target
$13.83
(+181.7%)
Revenue Growth (YoY)
-53.9%
Profit Margin
-102.8%
Share & Embed Analysis
Last updated: September 12, 2026 11:13 PM ET
Data refreshes hourly during market hours. Next update: 12:13 AM
Data refreshes hourly during market hours. Next update: 12:13 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRCA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
